In Gilead Sciences (NASDAQ: GILD) SIMPLE Trial, remdesivir had Adverse Events as high as 55% versus 45% in the Standard of Care (SOC). In April, this paltry trial data earned remdesivir an emergency use authorization. In comparison to leronlimab, remdesivir had significantly worse safety data and only a 4 day reduction in the time to recovery. In the active arm, leronlimab only had 14% SAEs versus 39% SAEs in the placebo group. Dissecting the data even more there is an even more powerful finding. The press release stated “none of the SAEs in leronlimab arm were deemed related to study drug administration by the investigators.”

https://insiderfinancial.com/cytodyns-otcmkts...ssion=true